Association of pro-inflammatory cytokines, adipokines & oxidative stress with insulin resistance & non-alcoholic fatty liver disease

Indian Journal of Medical Research

Volumn 136, Issue 2, 2012, Pages 229-236

  Kumar, Ramesh ^a   Prakash, Shyam ^a   Chhabra, Shruti ^a   Singla, Vikas ^a   Madan, Kaushal ^a   Datta Gupta, S ^a   Panda, Subrat K ^a   Khanal, Shankar ^a   Acharya, Subrat K ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Adipokines; Chronic hepatitis B; Cytokines; Insulin resistance; NAFLD; Oxidative stress

Indexed keywords

ADIPONECTIN; ASCORBIC ACID; INSULIN; INTERLEUKIN 1; INTERLEUKIN 6; LEPTIN; MALONALDEHYDE; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BLOOD LEVEL; BODY MASS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; ENZYME BLOOD LEVEL; FEMALE; HEPATITIS B; HORMONE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID PEROXIDATION; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; OBESITY; OXIDATIVE STRESS; PILOT STUDY; PROTEIN BLOOD LEVEL; VITAMIN BLOOD LEVEL; WAIST HIP RATIO;

ADIPOKINES; ADULT; ASCORBIC ACID; CYTOKINES; FATTY LIVER; FEMALE; HEPATITIS B, CHRONIC; HUMANS; INDIA; INFLAMMATION; INSULIN; INSULIN RESISTANCE; LIPID PEROXIDATION; LIVER; MALE; MALONDIALDEHYDE; OBESITY; OXIDATIVE STRESS; STATISTICS AS TOPIC; SUPEROXIDE DISMUTASE;

EID: 84866747705     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. McCullough AJ. Pathophysiology of Nonalcoholic Steatohepatitis. J Clin Gastroenteol 2006; 40 (Suppl1): S17-29.
2. Das K, Das K, Mukherjee PS, Ghosh A, Ghosh S, Mridha AR, et al. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. Hepatology 2010; 51: 1593-1602.
3. Amarapurkar DN, Hashimoto E, Lesmana LA, Sollano JD, Chen PJ, Goh KL for the Asia-Pacific Working Party on NAFLD. How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences? J Gastroenterol Hepatol 2007; 22: 788-793.
4. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998; 114: 842-845.
5. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003; 112: 91-100.
6. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91.
7. Jarrar MH, Baranova A, Collantes R, Ranard B, Stepanova M, Bennett C, et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008; 27: 412-421.
8. Madan K, Batra Y, Gupta SD, Chander B, Rajan KD, Tewari MS, et al. Non-alcoholic fatty liver disease may not be a severe disease at presentation among Asian Indians. World J Gastroenterol 2006; 12: 3400-3405.
9. Duseje A, Das A, Das R, Dhiman RK, Chawla A, Bhansali A, et al. The Clinicopathological Profile of Indian Patients with Nonalcoholic Fatty Liver Disease (NAFLD) is Different from that in the west. Dig Dis Sci 2007; 52: 2368-2374.
10. Duseja A, Das R, Nanda M, Das A, Garewal G, Chawla Y. Nonalcoholic steatohepatitis in Asian Indians is neither associated with iron overload nor with HFE gene mutations. World J Gastroenterol 2005; 11: 393-395.
11. Petersen KF, Dufour S, Feng J, Befroy D, Dziura J, Man CD, et al. Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men. Proc Nat Acad Sci 2006; 103: 18273-18277.
12. Letteron P, Fromenty B, Terris B, Degott C, Pessayre D. Acute and chronic hepatic steatosis lead to in vivo lipid peroxidation in mice. J Hepatol 1996; 24: 200-208.
13. Yang S, Zhu H, Li Y, Lin H, Gabrielson K, Trush MA, Diehl AM. Mitochondrial adaptations to obesity-related oxidant stress. Arch Biochem Biophys 2000; 378: 259-268.
14. World Health Organization, Department of Noncommunicable Disease Surveillance. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Geneva: WHO; 1999. Available at: www.staff.ncl.ac.uk/philip.home/who_dmg.pdf, accessed on July 8, 2001.
15. Heng D, Ma S, Lee JJM, Tai BC, Mak KH, Hughes K, et al. Modification of the NCEP ATP III definitions of the metabolic syndrome for use in Asians identifies individuals at risk of ischemic heart disease. Atherosclerosis 2006; 186: 367-373.
16. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-2474.
17. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-435.
18. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and B-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
19. Belch JJF, Bridges AB, Scott N. Oxygen free radicals and congestive heart failure. Br Heart J 1991; 65: 215-218.
20. Marklund S, Marklund G. Involvement of superoxide anion radical in the autooxidation of pyrogallol and a convenient assay for SOD. Eur J Biochem 1974; 47: 469-474.
21. Okamura M. An improved method for determination of L-ascorbic acid and L-dehydroascorbic acid in blood plasma. Clin Chim Acta 1980; 103: 259-268.
22. Benzie IFF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": the FRAP assay. Anal Biochem 1996; 239: 70-76.
23. Day CP. From fat to inflammation. Gastroenterology 2006; 130: 207-210.
24. Wieckowska A, Papouchado BG, Li Z, Lopez R, Zein NN, Feldstein AE. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol 2008; 103: 1372-1379.
25. Bouloumié A, Curat CA, Sengenès C, Lolmède K, Miranville A, Busse R. Role of macrophage tissue infiltration in metabolic diseases. Curr Opin Clin Nutr Metab Care 2005; 8: 347-354.
26. Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 1998; 83: 847-850.
27. Motoshima H, Wu X, Sinha MK, Hardy VE, Rosato EL, Goldstein BJ. Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes: effects of insulin and rosiglitazone. J Clin Endocrinol Metab 2002; 87: 5662-5667.
28. Wigg AJ, Robert-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxemia and tumor necrosis factor alfa in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001; 48: 206-211.
29. Yamashita A, Soga Y, Iwamoto Y, Yoshizawa S, Iwata H, Kokeguchi S, et al. Macrophage-adipocyte interaction: marked interleukin-6 production by lipopolysaccharide. Obesity (Silver Spring) 2007; 15: 2549-2552.
30. Rioda SM, Mclver CJ, Wakefield D, Duncombe VM, Bolin TD, Thomas MC. Mucosal cytokine production in small-intestinal bacterial overgrowth. Scand J Gastroenterol 1996: 31: 977-984.
31. Tsochatzis E, Papatheodoridis GV, Hadziyannis E, Georgiou A, Kafiri G, Tiniakos DG, et al. Serum adipokine levels in chronic liver diseases: association of resistin levels with fibrosis severity. Scand J Gastroenterol 2008; 43: 1128-1136.
32. Angulo P, Alba LM, Petrovic LM, Adams LA, Lindor KD, Jensen MD. Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. J Hepatol 2004; 41: 943-949.
33. Videla LA, Rodrigo R, Orellana M, Fernandez V, Tapia G, Quiñones L, et al. Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients. Clin Sci 2004; 106: 261-268.